The burgeoning field of metabolic disease management is witnessing a exciting convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://biopeptidestore.com/